K36 Therapeutics Secures $70M Series B Funding to Support KTC-1001 for Multiple Myeloma Patients

Cambridge, MA, June 28, 2023 (PRNewswire) -- K36 Therapeutics, a clinical-stage biotech company, has successfully raised $70M in a Series B financing round led by Nextech Invest, LTD with participation from Bristol Myers Squibb and others. The funds will support the development of KTX-1001, a first-in-class small molecule inhibitor targeting replaced and refractory multiple myeloma.

Read full article here.